AIM Action

AIM ImmunoTech is a clinical-stage biopharmaceutical company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases. The company's lead product, Ampligen (rintatolimod), is a double-stranded RNA molecule that acts as a selective Toll-like receptor 3 (TLR3) agonist, designed to modulate the immune system. Ampligen is currently being evaluated in various clinical trials for indications including pancreatic cancer, ovarian cancer, and Long COVID. AIM ImmunoTech also produces Alferon N Injection, an FDA-approved natural source interferon for the treatment of refractory or recurrent external condylomata acuminata. The company aims to leverage its expertise in immunology to address significant unmet medical needs in oncology and infectious diseases.